Lenalidomid Zentiva (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, changing the complex’s substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, which are essential for malignant plasma‑cell survival. The result is reduced tumor growth, decreased angiogenesis, and enhanced immune‑mediated tumor cell killing.

The specific dose of Lenalidomid Zentiva is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Dosing regimens are individualized and may be adjusted during treatment; patients should follow the exact instructions provided by their healthcare professional.

Lenalidomid Zentiva is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It must not be used during pregnancy, and effective contraception is required for both men and women of reproductive potential. Breastfeeding is not recommended, as the drug may be excreted in milk and affect the infant.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, then confirms pricing, availability, shipping conditions, and any necessary import documentation before finalising the transaction.

The primary alternatives to lenalidomide are thalidomide and pomalidomide, which belong to the same immunomodulatory imide drug (IMiD) class. Lenalidomide generally offers a more favorable safety profile than thalidomide, especially regarding peripheral neuropathy, while providing stronger anti‑myeloma activity than thalidomide. Compared with pomalidomide, lenalidomide is often used earlier in therapy and has a longer history of clinical use.

Store Lenalidomid Zentiva at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original blister pack or container, protect them from moisture, light, and excessive heat. Do not store in the bathroom or near a kitchen sink. Ensure the product is kept out of reach of children.

Lenalidomid Zentiva is taken orally, usually with a glass of water. It may be taken with or without food, but patients should follow the specific instructions of their prescriber. The tablets are swallowed whole and not crushed or chewed unless directed by a healthcare professional.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to infections, and the rare possibility of secondary primary malignancies. Patients should promptly report any signs of unexplained swelling, pain, fever, or unusual bleeding to their physician.

Lenalidomid Zentiva should not be used by individuals who are pregnant, planning to become pregnant, or who are not using reliable contraception. It is also contraindicated in patients with known hypersensitivity to lenalidomide or any component of the formulation, and caution is advised in those with severe renal impairment unless dose‑adjusted by a specialist.